nialamide nialamide nialamide (niamid, niamide, nuredal, surgex) is a non-selective, irreversible monoamine oxidase inhibitor (maoi) of the hydrazine class that was used as an antidepressant. it was withdrawn by pfizer several decades ago due to the risk of hepatotoxicity. nialamideclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc coden06af02 (who) legal statuslegal status au: s4 (prescription only) identifiers iupac name n-benzyl-3-(n-(pyridine-4-carbonyl)hydrazino)propanamide cas number51-12-7 ypubchem cid4472drugbankdb04820 ychemspider4317 yuniit2q0rym725keggd07337 ychebichebi:94510chemblchembl1256841comptox dashboard (epa)dtxsid1023362 echa infocard100.000.073 chemical and physical dataformulac16h18n4o2molar mass298.346 g·mol−13d model (jsmol)interactive image smiles o=c(nnccc(=o)ncc1ccccc1)c2ccncc2 inchi inchi=1s/c16h18n4o2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19h,8,11-12h2,(h,18,21)(h,20,22) ykey:noiiuhrquvnidd-uhfffaoysa-n y (verify) side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarely leukopenia and hepatitis. as with other maois, a hypertensive crisis can be triggered by co-ingestion of tyramine. it is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. the recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day. the antiatherogenic activity of nialamide was used to design pyridinolcarbamate.